Szczeklik A
Department of Allergy and Clinical Immunology, Copernicus Academy of Medicine, Cracow, Poland.
Int Arch Allergy Appl Immunol. 1989;90 Suppl 1:70-5. doi: 10.1159/000235079.
Aspirin-induced asthma (AIA) is a distinct clinical syndrome, present in about 10% of adult asthmatics. Precipitation of the asthmatic attacks by aspirin and other nonsteroidal anti-inflammatory drugs is the hallmark of the syndrome. The idea that the attacks might result from the specific inhibition of a single enzyme in the respiratory tract, namely cyclooxygenase, has found support in experimental and clinical studies, and has generated a number of new hypotheses on the mechanism of bronchoconstriction. These hypotheses, operating within the frame of cyclooxygenase theory, point to the involvement of leukotrienes, platelets or chronic viral infection. Progress in studies on AIA has improved our knowledge on the drugs - safe and contraindicated - in this relatively common and fascinating clinical syndrome. Studies on mechanisms operating in AIA might eventually lead to new insights in pathogenesis of bronchial asthma.
阿司匹林诱发的哮喘（AIA）是一种独特的临床综合征，约10%的成年哮喘患者中存在该综合征。阿司匹林和其他非甾体抗炎药引发哮喘发作是该综合征的标志。哮喘发作可能源于呼吸道中单一酶（即环氧化酶）的特异性抑制这一观点，已在实验和临床研究中得到支持，并催生了一些关于支气管收缩机制的新假说。这些在环氧化酶理论框架内起作用的假说表明白三烯、血小板或慢性病毒感染参与其中。对AIA的研究进展增进了我们对这种相对常见且引人关注的临床综合征中药物安全性和禁忌的了解。对AIA发病机制的研究最终可能会为支气管哮喘的发病机制带来新的见解。
